Managing Students with Seizures:
Continuing Education Class with Credits
The National Association of School Nurses (NASN) and The Epilepsy Foundation have teamed up to create a continuing education program for school nurses. The program is titled "Managing Students with Seizures: A Training for School Nurses." Because the NASN is involved, nurses can be assured that the objectives and content are specifically designed to meet the real and immediate needs of school nurses. This program is generally a three and one-half hour event with 3.2 contact hours awarded.
To learn more, please visit:
Reference:
- "Managing Students with Seizures," National Association of School Nurses, Copyright 2007 NASN. Located at http://www.nasn.org/Default.aspx?tabid=120. Accessed on May 24, 2007.
IMPORTANT SAFETY INFORMATION
DIASTAT® AcuDial™ (diazepam rectal gel) is a gel formulation of diazepam intended for rectal administration in the management of selected, refractory patients with epilepsy, on stable regimens of AEDs, who require intermittent use of diazepam to control bouts of increased seizure activity for patients 2 years and older.
In clinical trials with DIASTAT®, the most frequent side effect was somnolence (23%). Less frequent adverse events reported were dizziness, headache, pain, vasodilation, diarrhea, ataxia, euphoria, incoordination, asthma, rash, abdominal pain, nervousness and rhinitis (1%-5%). Please see full DIASTAT AcuDial Prescribing Information.
DIASTAT® AcuDial™ (diazepam rectal gel) is a gel formulation of diazepam intended for rectal administration in the management of selected, refractory patients with epilepsy, on stable regimens of AEDs, who require intermittent use of diazepam to control bouts of increased seizure activity for patients 2 years and older.
In clinical trials with DIASTAT®, the most frequent side effect was somnolence (23%). Less frequent adverse events reported were dizziness, headache, pain, vasodilation, diarrhea, ataxia, euphoria, incoordination, asthma, rash, abdominal pain, nervousness and rhinitis (1%-5%). Please see full DIASTAT AcuDial Prescribing Information.
© Valeant Pharmaceuticals North America 2007
Legal and Privacy Statement
DIASTAT® AcuDial™ is a registered trademark of Valeant Pharmaceuticals North America. D896-0607 Site Map